Literature DB >> 34283056

Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response.

Konsta Kukkonen1, Sinja Taavitsainen1, Laura Huhtala1, Joonas Uusi-Makela1, Kirsi J Granberg1, Matti Nykter1, Alfonso Urbanucci2.   

Abstract

The dysregulation of chromatin and epigenetics has been defined as the overarching cancer hallmark. By disrupting transcriptional regulation in normal cells and mediating tumor progression by promoting cancer cell plasticity, this process has the ability to mediate all defined hallmarks of cancer. In this review, we collect and assess evidence on the contribution of chromatin and epigenetic dysregulation in prostate cancer. We highlight important mechanisms leading to prostate carcinogenesis, the emergence of castration-resistance upon treatment with androgen deprivation therapy, and resistance to antiandrogens. We examine in particular the contribution of chromatin structure and epigenetics to cell lineage commitment, which is dysregulated during tumorigenesis, and cell plasticity, which is altered during tumor progression.

Entities:  

Keywords:  androgen receptor signaling inhibitors; castration resistant prostate cancer; chromatin; chromatin regulators alterations; chromatin-associated factors; drug resistance; epigenetics; lineage commitment; lineage plasticity; prostate cancer

Year:  2021        PMID: 34283056     DOI: 10.3390/cancers13133325

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Epigenetic Coregulation of Androgen Receptor Signaling.

Authors:  Rayzel C Fernandes; Damien A Leach; Charlotte L Bevan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.

Authors:  Juan C Pardo; Vicenç Ruiz de Porras; Joan Gil; Albert Font; Manel Puig-Domingo; Mireia Jordà
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

Review 3.  To bind or not to bind: Cistromic reprogramming in prostate cancer.

Authors:  Michelle Shen; Léa-Kristine Demers; Swneke D Bailey; David P Labbé
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.